www.siga.com
Open in
urlscan Pro
141.193.213.10
Public Scan
Submitted URL: http://www.siga.com/
Effective URL: https://www.siga.com/
Submission: On October 23 via api from US — Scanned from DE
Effective URL: https://www.siga.com/
Submission: On October 23 via api from US — Scanned from DE
Form analysis 1 forms found in the DOM
/
<form class="search" action="/"><input type="text" name="s" placeholder="Search"><input type="submit" value="Submit"></form>Text Content
Close * About SIGA * Products * Investors * News * Careers * Contact SIGA: HUMAN BIOARMOR Providing solutions for unmet needs in health security * About SIGA * Products * Investors * News * Careers * Contact Menu SIGA IS MONITORING THE GROWING MONKEYPOX OUTBREAK AND SUPPORTS THE RESPONSE TPOXX IS APPROVED BY THE U.S. FDA AND HEALTH CANADA FOR THE TREATMENT OF SMALLPOX Tecovirimat-SIGA is approved by the EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus NAMED 27TH ON THE FORBES LIST OF BEST SMALL CAP COMPANIES HEALTH SECURITY We are a public, commercial-stage pharmaceutical company focused on providing solutions for unmet needs in health security. * 1 * 2 * 3 * 4 Click here to learn more about how SIGA is monitoring the monkeypox outbreak. U.S. providers seeking guidance on obtaining TPOXX please visit CDC.gov For foreign governments or other inquiries about TPOXX (Tecovirimat-SIGA), please contact us at monkeypox@siga.com (Note: TPOXX is approved by the U.S. FDA and Health Canada for the treatment of Smallpox; Tecovirimat-SIGA is approved by the EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus) OUR PIPELINE Attractive product and market expansion opportunities OUR TEAM Experienced team of scientists and business leaders OUR PARTNERS Rich history of successful partnerships to support our vision SIGA TECHNOLOGIES RECEIVES APPROVAL FROM UK FOR TECOVIRIMAT Learn More NEWS & PRESS RELEASES * SIGA PROVIDES UPDATE ON PROGRESS IN CLINICAL TRIALS TO ASSESS USE OF TPOXX ® (TECOVIRIMAT) FOR TREATMENT OF MONKEYPOX Oct 12, 2022 * SIGA TECHNOLOGIES ANNOUNCES NEW CONTRACT AWARDED BY U.S. DEPARTMENT OF DEFENSE FOR THE PROCUREMENT OF UP TO $10.7 MILLION OF ORAL TPOXX® Sep 29, 2022 * SIGA ANNOUNCES APPROXIMATELY $16 MILLION OF INTERNATIONAL PROCUREMENT ORDERS RECEIVED IN AUGUST AND EARLY SEPTEMBER FOR ORAL TPOXX® (TECOVIRIMAT) Sep 26, 2022 More News HEALTH SECURITY IS A $12.7 BILLION MARKET Medical countermeasures for biological, chemical, radiological and nuclear attacks, as well as vaccines, therapeutics and diagnostics for emerging infectious diseases SIGA: HUMAN BIOARMOR * Corporate Headquarters 31 East 62nd Street New York, NY 10065 (212) 672-9100 * SIGA Development Operations 4575 SW Research Way, Suite 110 Corvallis, OR 97333 (541) 753-2000 HCP and Product Inquiries: Call 541-766-3744 * Privacy Notice © 2022 SIGA Technologies, All Rights Reserved